comparemela.com

Latest Breaking News On - Interventional systems - Page 12 : comparemela.com

Lawsuits against B Braun allege carcinogenic gas was released from Hanover Township plant

Specter | Kline & Specter PHILADELPHIA – Sixteen people who developed cancer, some of them fatally, and their families have brought suit against German medical device manufacturer B. Braun, alleging that emissions of a carcinogenic gas called ethylene oxide (EtO) from the company’s plant in Hanover Township led to their illnesses. The plaintiffs filed suit in the Philadelphia County Court of Common Pleas on May 4 versus B. Braun Medical, Inc., B. Braun Of America, Inc., B. Braun Melsungen AG, B. Braun Cegat, LLC, B. Braun Interventional Systems, Inc. and John Doe, all of Bethlehem. Ethylene oxide, or EtO, a chemical used to sterilize medical equipment, was deemed a human carcinogen by the U.S. Environmental Protection Agency. EPA data, according to plaintiff counsel, showed that the cancer risk from the colorless gas present in one Hanover Township neighborhood was substantially higher than the average amount measured statewide.

No Patient Asks to Be Stuck More than Once - B Braun Unveils New Data-Driven Program Designed to Improve Patients Experience with Intravenous Therapies

Share this article BETHLEHEM, Pa., April 29, 2021 /PRNewswire/ B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today unveiled Peripheral Advantage ®, a new program that is designed to improve patients experience with peripheral intravenous (IV) therapy. The comprehensive program combines clinical instruction, data-driven insights and advanced tools to empower nurses to achieve first-stick success and help prevent many of the complications associated with peripheral IV therapy. Peripheral Advantage, which is now available to all hospitals nationwide, addresses a long tolerated, yet unacceptable reality: Although vascular access is the most common invasive procedure, most nurses are not provided with the training, techniques or tools they need to achieve first-stick success. Only 57% or less of nursing students receive any form of Peripheral Intravenous Catheter (PIVC) training.

Terumo is building a Global Therapeutic Interventional Oncology team to offer more therapeutic solution to cancer patients

Terumo is building a Global Therapeutic Interventional Oncology team to offer more therapeutic solution to cancer patients News provided by Share this article Share this article LEUVEN, Belgium, April 12, 2021 /PRNewswire/ Terumo is proud to announce the launch of its Global Therapeutic Interventional Oncology team as of April 1st, 2021. This reflects Terumo s aspiration to be a Global leader in the field of Interventional Oncology by focusing on improving patient s quality of life and survival. This organization will be comprised of Medical Strategy, Research & Development, Software Development, Medical Imaging Discovery, and Operations. It will be entirely dedicated to the development of Therapeutic Interventional Oncology solutions for patients with cancer. This team will be led by Laurent Domas, Vice President, Global Interventional Oncology Strategy and Therapy Development.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.